skip to Main Content
 

AIM round-up: Genedrive, MyHealthChecked, Eve Sleep

*

Having tailed off at the end of last week, London’s AIM Index popped higher this morning, although failed to capitalise on those gains, closing the session up almost 9 points at 1192.17.

  • Genedrive up 28%
  • MyHealthChecked up 27%
  • Eve Sleep up 21%
  • Braveheart Investment Group down 31%
  • Lansdowne Oil and Gas down 19%

Genedrive [LON:GDR] soared 27% on Monday, although the only news issued by the company was pointing towards an investor presentation at the end of the month. The company is involved with COVID testing and looking across the market, this is clearly an area where there’s an element of rebalancing in play right now. The opening of a US sales channel could well be offering some fresh optimism here.


MyHealthChecked [LON:MHC] jumped towards the top of the board in the week’s opening session, adding almost 27% by the close. A note published by the business this morning acknowledged speculation over the weekend that a potential contract may be in the pipeline, but this simply acknowledged that a statement at the end of last year saw MHC included in a UK government listing for private testers. The company continues by noting that whilst there are commercial discussions ongoing, no contracts have been signed and that further updates will be forthcoming should these come to fruition.

A notable mention for Eve Sleep [LON:EVE], the mattress manufacturer which put in a solid performance by adding another 20%. That helps recoup some of the losses from the last two weeks and although there’s no firm news, the rally appears to have been fuelled by renewed interest in anything CBD related and earlier narratives of tie-ups in this space.

Braveheart Investment Group [LON:BRH] slipped to the foot of the table today, off some 31% following an update from the business on its wholly owned Paraytec division. Again this looks at COVID testing and the company has developed one which offers a result in under 120 seconds. However with the clinical trial process set to take two months, the duration here seems to have spooked some investors. The ability to generate test results in a matter of seconds will be transformative – with shares at two-week lows, do they now offer value?

Lansdowne Oil and Gas [LON:LOGP] slipped 19%, following an update on a farm-out agreement covering a drill site where the company has some exposure. To get this to the next stage, the partner needed to secure financing but this is still to emerge. That has seen a two month extension to the agreement, which comes with a consequent delay to any cashflow for Lansdowne.

Like this article? Sign up to our free newsletter.

This article does not constitute investment advice. Do your own research or consult a professional advisor.

The Armchair Trader's 'How to' Guides

Read our latest in-depth company reports

Detailed reviews of selected companies and investment trusts.

Listen to our latest podcast episodes

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

Aquis
FP Markets
IG
Pepperstone
WisdomTree
CME Group
Back To Top